The incubation of cells with anlotinib (0.125-5.0 μmol/L) decreased the expression of phosphorylated forms of AKT, ERK1/2, and STAT3 in all CRC cells, which indicated that the MDR reversal effect of anlotinib in HT-29, LoVo, HCT116, or HCT116/L cells was dependent on the inhibition of AKT, ERK1/2, and STAT3 phosphorylation. Here, STAT3 is linked to colorectal carcinoma.